BioAge Labs, Inc. (BIOA)
2025-06-30 | 2025-03-31 | |||
|---|---|---|---|---|
| Collaboration revenue | 2,412 | 1,451 | ||
| Research and development | 19,844 | 11,109 | ||
| General and administrative | 7,339 | 6,788 | ||
| Total operating expenses | 27,183 | 17,897 | ||
| Loss from operations | -24,771 | -16,446 | ||
| Interest expense | 201 | 255 | ||
| Interest and other income (expense), net | 3,420 | 3,714 | ||
| Loss on extinguishment of debt | - | - | ||
| Gain (loss) from changes in fair value of warrants | -11 | 59 | ||
| Total other income (expense), net | 3,208 | 3,518 | ||
| Net loss | -21,563 | -12,928 | ||
| Unrealized holding gains on available-for-sale investments | - | 29 | ||
| Foreign currency translation adjustment | -52 | -10 | ||
| Total other comprehensive income (loss) | -52 | 19 | ||
| Total comprehensive loss | -21,615 | -12,909 | ||
| Earnings per share, basic, total | -0.6 | -0.36 | ||
| Net loss per share attributable to common stockholders, diluted | -0.6 | -0.36 | ||
| Weighted average number of shares outstanding, basic, total | 35,850,037 | 35,850,037 | ||
| Weighted average number of shares outstanding, diluted, total | 35,850,037 | 35,850,037 | ||